# Imspc Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imspc-biotech

- Industry: Healthcare IT
- Headquarters: Suzhou, China
- Website: www.imspc.life
- Latest round: Angel (May 28, 2024)
- Investors on record: 1

## About

Established in 2023 and based in Suzhou, China, Imspc Biotech is a healthcare IT company that focuses on providing medical solutions for hyperuricemia. The CEO of this company,  Xiang Leng, has worked for Johnson & Johnson and Ping An and has nearly two decades of healthcare experience. It released a gout risk assessment test based on Liquid Chromatograph Mass Spectrometer (LC-MS) technology on April 20, 2024. It has partnerships with Guangzhou Jinyu Investment and Consulting Co., Ltd and Biotree. In May 2024, it closed an angel funding.

The company’s main business is the provision of precise diagnostic services and innovative treatment solutions for hyperuricemia and gout. The company’s self-developed products include mass spectrometry testing for small molecule metabolites and AI algorithms for gout risk assessment. Its products and services are used in the field of medical diagnostics, specifically for the early detection and treatment of hyperuricemia and gout. It also provides gout-targeted drugs, health management service system, health insurance, customized nutritional products, and medical assistance.

Imspc Biotech generates revenue by providing comprehensive diagnostic services.

## Funding rounds

- Angel, May 28, 2024 — YSCapital

## Investors

- YSCapital (https://capitalatlas.ai/funds/yscapital) — Angel